Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Duality Biotherapeutics, Inc. ( (HK:9606) ) has provided an announcement.
Duality Biotherapeutics, Inc. announced the successful passage of all proposed resolutions during its Annual General Meeting held on June 20, 2025. The resolutions included the adoption of the company’s audited financial statements for 2024, re-election of directors, re-appointment of auditors, and granting of mandates to the directors for share repurchase and issuance. These decisions reflect strong shareholder support and are expected to enhance the company’s governance and operational flexibility.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$270.34 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Average Trading Volume: 735,178
Learn more about 9606 stock on TipRanks’ Stock Analysis page.